ArticleJournal of virology1996
A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1.
Article in Journal of virology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 55 citations in OpenAlex.
- Bone Marrow Gene Therapy for HIV/AIDS.Viruses · 2015Review
- RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside.The Yale journal of biology and medicine · 2011Review
- Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- Inhibition of hepatitis B virus X gene expression by novel DNA enzymes.The Biochemical journal · 2001Article
- Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- Gene therapy for HIV infections: Intracellular immunization.The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses · 1999Article
- Polyvalent Rev decoys act as artificial Rev-responsive elements.Journal of virology · 1999Article
- Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- Inhibition of transcription by the TAR RNA of HIV-1 in a nuclear extract of HeLa cells.Nucleic acids research · 1997Article
- Antiviral ribozymes. New jobs for ancient molecules.Molecular biotechnology · 1997Review
- A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml.Nucleic acids research · 1997Article
- Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades.Journal of virology · 1997Article
- A ribozyme targeted to cleave the polymerase gene sequences of different foot-and-mouth disease virus (FMDV) serotypes.Virus genes · 1997Article
- RNA-mediated virus resistance in transgenic plants.Archives of virology · 1996Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
We have previously shown that hairpin ribozymes targeting the human immunodeficiency virus (HIV) genome can effectively inhibit virus replication in a variety of primary and cultured hematopoietic cells. To further increase antiviral potency and minimize the chance of viral resistance, we have now cloned the stem-loop II sequences of the HIV type 1 Rev response element into ribozyme transcription cassettes. Fusion RNA molecules were shown to function both as RNA decoys and ribozymes. Stable Molt-4/8 cell lines expressing fusion RNA of stem-loop II and a ribozyme directed at the HIV-type 1 U5 sequence (MSLMJT) or its disabled counterpart (MSLdMJT) were generated. The expression of fusion RNA was persistent for at least 6 months without apparent cytotoxicity. When virus inhibition was examined after the cocultivation of transduced cells with chronically infected Jurkat cells, much greater protection was observed in MSLMJT cells than in MSLdMJT or MMJT (expressing only the ribozyme) cells. Furthermore, to specifically compare the ribozyme activities in various transduced cells, we determined the quantitative levels of proviral DNA in the first round of virus replication (7 h after infection with HXB2). By competitive PCR, the proviral DNA levels in MSLMJT and MMJT cells were found to be reduced to 1/7 and 1/3, respectively, compared with those in MSLdMJT and MdMJT cells. These results suggest not only that the greater inhibition afforded by this fusion RNA was due to its function both as decoy and ribozyme but also that the ribozyme activity may be facilitated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.